It is interesting to note that this clinical sequence was described in a context of a standard treatment of diabetes which encompassed twice daily rapid-acting insulin administrations, before the diabetes control and complications trials (DCCT) study shifted “basic” diabetes control to three injections a day [24]. The gene discussed is INS; the disease is diabetes mellitus.